These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9802775)

  • 1. Autoimmunity and intraperitoneal insulin treatment by programmable pumps: lack of relationship.
    Lassmann-Vague V; SanMarco M; LeJeune PJ; Alessis C; Vague P; Belicar P
    Diabetes Care; 1998 Nov; 21(11):2041-4. PubMed ID: 9802775
    [No Abstract]   [Full Text] [Related]  

  • 2. Current status and future of implantable insulin pumps for the treatment of diabetes.
    Catargi B
    Expert Rev Med Devices; 2004 Nov; 1(2):181-5. PubMed ID: 16293038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunogenetics and new therapies in type I diabetes mellitus].
    Gannage-Yared MH
    J Med Liban; 1999; 47(2):139-43. PubMed ID: 10410471
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of abdominal location of the catheter on the efficacy of intraperitoneal insulin infusion using implantable and programmable pumps in type I diabetes.
    Pinget M; Jeandidier N; Keipes M; Louy S; Vetter A
    Transplant Proc; 1992 Jun; 24(3):945-6. PubMed ID: 1604676
    [No Abstract]   [Full Text] [Related]  

  • 5. Insulin pumps.
    Torrance T; Franklin V; Greene S
    Arch Dis Child; 2003 Nov; 88(11):949-53. PubMed ID: 14612350
    [No Abstract]   [Full Text] [Related]  

  • 6. Insulin pump--a review.
    Selvan C; Ghosh S; Mukhopadhyay S
    J Indian Med Assoc; 2013 Nov; 111(11):746-50. PubMed ID: 24968483
    [No Abstract]   [Full Text] [Related]  

  • 7. Long term safety and efficacy of intraperitoneal insulin infusion by means of implantable pumps.
    Pinget M; Jeandidier N
    Horm Metab Res; 1998 Aug; 30(8):475-86. PubMed ID: 9761375
    [No Abstract]   [Full Text] [Related]  

  • 8. Insulin Pumps.
    Pickup JC
    Diabetes Technol Ther; 2018 Feb; 20(S1):S30-S40. PubMed ID: 29437475
    [No Abstract]   [Full Text] [Related]  

  • 9. SHBG (sex hormone binding globulin) levels in insulin dependent diabetic patients according to the route of insulin administration.
    Lassmann-Vague V; Raccah D; Pugeat M; Bautrant D; Belicar P; Vague P
    Horm Metab Res; 1994 Sep; 26(9):436-7. PubMed ID: 7835829
    [No Abstract]   [Full Text] [Related]  

  • 10. Intensive insulin therapy and insulin pumps.
    Bode BW
    Postgrad Med; 2002 Nov; 112(5 Suppl Designer):17-21. PubMed ID: 19667601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetic ketoacidosis caused by exposure of insulin to low temperature.
    Minuto N; Tambroni B; Vannati M; Emmanuele V; Russo C; Lorini R; d'Annunzio G
    Diabetes Technol Ther; 2010 Sep; 12(9):745-6. PubMed ID: 20687866
    [No Abstract]   [Full Text] [Related]  

  • 12. Closing the Loop.
    Nimri R; Audon P; Pinsker JE; Dassau E
    Diabetes Technol Ther; 2018 Feb; 20(S1):S41-S54. PubMed ID: 29437478
    [No Abstract]   [Full Text] [Related]  

  • 13. Implantable insulin pumps: an effective option with restricted dissemination.
    Spaan NA; Teplova AE; Renard E; Spaan JA
    Lancet Diabetes Endocrinol; 2014 May; 2(5):358-60. PubMed ID: 24795244
    [No Abstract]   [Full Text] [Related]  

  • 14. Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems.
    Olsen CL; Chan E; Turner DS; Iravani M; Nagy M; Selam JL; Wong ND; Waxman K; Charles MA
    Diabetes Care; 1994 Mar; 17(3):169-76. PubMed ID: 8174443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre trial of a programmable implantable insulin pump in type I diabetes. The Point Study II Group.
    Int J Artif Organs; 1995 Jun; 18(6):322-5. PubMed ID: 8593967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of long-term intraperitoneal insulin administration with implantable programmable pumps. Metabolic consequences.
    Lassmann-Vague V; Belicar P; Raccah D; Vialettes B; Sodoyez JC; Vague P
    Diabetes Care; 1995 Apr; 18(4):498-503. PubMed ID: 7497859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fasting and postprandial plasma glucose and peripheral insulin levels in insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus subjects during continuous intraperitoneal versus subcutaneous insulin delivery.
    Hermans MP; van Ypersele de Strihou M; Ketelslegers JM; Squifflet JP; Buysschaert M
    Transplant Proc; 1995 Dec; 27(6):3329-30. PubMed ID: 8539974
    [No Abstract]   [Full Text] [Related]  

  • 18. Insulin pumps: closer to a pancreas.
    Tucker SE
    Diabetes Forecast; 2015; 68(2):58-63. PubMed ID: 25812187
    [No Abstract]   [Full Text] [Related]  

  • 19. Mycobacterium fortuitum infection in continuous subcutaneous insulin infusion sites.
    López Aventín D; Rubio González B; Petiti Martín G; Segura S; Rodríguez-Peralto JL; Riveiro-Falkenbach E; Puig J; Pujol RM
    Br J Dermatol; 2014 Aug; 171(2):418-20. PubMed ID: 24588257
    [No Abstract]   [Full Text] [Related]  

  • 20. Diabetic Ketoacidosis Among Patients Treated With Continuous Subcutaneous Insulin Infusion.
    Dogan ADA; Jørgensen UL; Gjessing HJ
    J Diabetes Sci Technol; 2017 May; 11(3):631-632. PubMed ID: 27595713
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.